Bretylium

Bretylium

Clinical data
Pregnancy category	AU: C US: C (Risk not ruled out)
Routes of administration	IV, IM
ATC code	C01BD02 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	NA
Protein binding	NA
Metabolism	None
Elimination half-life	7-8 hours
Excretion	Renal
Identifiers
IUPAC name (2-bromophenyl)methyl-ethyl-dimethyl-ammonium
CAS Number	59-41-6
PubChem CID	2431
DrugBank	APRD00830
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C11H17BrN+
Molar mass	243.163 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Bretylium (also bretylium tosylate) blocks the release of noradrenaline from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, & other specialties for the acute management of ventricular tachycardia & ventricular fibrillation. It is contraindicated in patients with AV (atrioventricular) heart block or digoxin toxicity.

Bretylium is only used in an ICU setting and should not be used elsewhere due to its dramatic actions and its predominant side effect of hypotension.

Template:Antiarrhythmic agents

de:Bretylium hr:Bretilij

Template:WikiDoc Sources